Safety and Efficacy of WIN-901X in Asthma

• Status: Completed
• Trial end date: 2013-11-01
• Target enrollment: 0
• Participant gender: All

Summary

This clinical trial is designed to evaluate the efficacy, dose-response and safety of WIN-901X in Asthma patients.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Whanin Pharmaceutical Company

Criteria

Inclusion Criteria:

• Greater than or equal to 20 and less than 80 years of age

• Have physician diagnosed asthma with irreversible airway obstruction at least 6 months prior to the screening

• FEV1 between 60% and 85% before inhaling fast-acting bronchodilator at screening

• No history of smoking at least one year prior to the screening

• Having voluntarily signed an informed consent

Exclusion Criteria:

• Have visited emergency room due to the worsening asthma symptoms, within 4 weeks before the screening

• Have been hospitalized due to an acute worsening of asthma within 3 months before the screening

• Have a history of laryngitis, pyrexia, sinusitis, otitis media, respiratory tract infection, and infectious rhinitis within 4 weeks prior to the screening

• Have malignant tumor